Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2018 07:35 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV

- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal”...
June 25, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Inclusion in Russell Microcap® Index

ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
June 04, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony

ATLANTA, GA and BOTHELL, WA, June 04, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
May 11, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update

ATLANTA, GA and BOTHELL, WA, May 11, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
May 10, 2018 08:30 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the Fred Hutch and Merck Infectious Disease Summit

- Presentation on Thursday, May 10 at 11:15 AM PDT - ATLANTA, GA and BOTHELL, WA, May 10, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical...
May 01, 2018 08:30 ET | Source: Cocrystal Pharma, Inc.

COCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING

TUCKER, GA and BOTHELL, WA, May 01, 2018 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP), (“Cocrystal” or the “Company”) a clinical stage biotechnology company focused on developing...
April 03, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus

– Company on track to commence patient enrollment and dosing in Q2 2018 – – Topline data from Phase 2a study expected in Q4 2018 – ATLANTA, GA and BOTHELL, WA, April 03,...
March 22, 2018 07:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business Outlook

–Company successfully completes uplisting to the NASDAQ Capital Market – –Company positioned to achieve clinical and regulatory milestones over the course of 2018– ATLANTA, GA and BOTHELL, WA, March...
March 12, 2018 08:30 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Uplist to The Nasdaq Capital Market

ATLANTA, GA and BOTHELL, WA, March 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
January 23, 2018 16:30 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Provides Update on Reverse Stock Split

- Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. 23, 2018 (GLOBE NEWSWIRE) --...